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Background
Nonsedating antihistamines are recommended as first
line treatment for patients with urticaria.
Methods
In our study, 30 patients with chronic urticaria for at
least six weeks were enrolled after an informed written
consent. Out of 30 patients 16 were females and 14
were males, in the age group of 16 yrs to 55 yrs (average
age 33 yrs).
Patients with urticaria activity score (UAS) of 3 or
more than 3 ,were started on tablet levocetirizine in a
dose of 10 mg at bedtime at the onset of the treatment.
Out of 30 patients only 5 patients were symptomatic
at the end of one week and were started on 20 mg of
levocetirizine. Three out of 5 patients were asympto-
matic after starting higher dose of 20 mg at the end of
2nd week with reduction in UAS. Twenty eight out of 30
patients showed good response and decrease in the UAS
within two weeks , with higher dose of levocetirizine.
However 2 patients showed no response to treatment
even with 20 mgs of levocetirizine.
Average UAS at 0 week was 4.767, it came down to 1.8
at the end of one week. At the end of two weeks UAS was
1.4. At the end of 4 weeks average UAS came down to 0.4,
showing a marked downward trend with high doses of
levocetirizine given at the very onset of the disease. There-
fore patients with higher UAS at the time of presentation
should be started on a higher dose of levocetirizine at the
onset of the treatment for better symptomatic relief and
suppression of the disease within one week.
Results
According to the findings in our study use of a higher
dose of non sedating antihistamine in patients with UAS
of 3 or more than 3 at the very start of the therapy
brings about a better control and rapid supression of
the symptoms, suggesting the need for “higher doses for
heavy hives”.
Conclusions
we suggest higher doses for heavy hives.
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